Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey
Articles > Article · 2020
Authors: Tansu YAMAZHAN, İlker TURAN, Galip ERSÖZ, Fulya GÜNŞAR, Hüsnü PULLUKÇU, Nilay Danis, Nalan Gülşen ÜNAL, Rukiye VARDAR, Nevin ORUÇ, Fatih TEKİN, Meltem TAŞBAKAN, Oğuz Reşat SİPAHİ, Ulus Salih AKARCA
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI Expanded, International, 2020, vol 31, pp 239-245
Summary
Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey.